Abstract
Insulin resistance (IR) plays an important role as a major determinant of Metabolic syndrome (MetS). Various methods are available for measuring insulin resistance but they are laborious, time-consuming, and costly. Therefore various surrogate markers and indices have been devised to simplify and improve the determination of insulin resistance. Recently, a new index, single point insulin sensitivity estimator (SPISE) was proposed in the European population and was found comparable to the gold standard test (hyperinsulinemic euglycemic glucose clamp).This study was planned to evaluate whether SPISE could be a useful potential low-cost indicator for predicting MetS with IR patients in Indian population. Eighty-three participants from outpatient care of AIIMS Rishikesh were evaluated after informed consent. They were divided into Metabolic syndrome (n = 56) and Non Metabolic Syndrome(n = 27), using South Asian Modified National Cholesterol Education Program- ATP-III criteria for metabolic syndrome. SPISE index, HOMA-IR, Insulin Resistance Index, Triglycerides to high-density lipoproteins cholesterol ratio (TG/HDL-C) were calculated for all the subjects. Receiver operating characteristic (ROC) curve was plotted to assess discriminatory ability of SPISE, HOMA-IR, TG/HDL-C ratio, IRI and hs-CRP to differentiate between IR(Metabolic syndrome) and non-IR (Non-Metabolic syndrome) subjects. SPISE has greater area under curve with better sensitivity and specificity compared to HOMA-IR, IRI, TG/HDL-C ratio and hs CRP. So, SPISE has better predictive ability than HOMA-IR, IRI, TG/HDL-C ratio and hs CRP to discriminate IR from non-IR cases. SPISE could be a useful potential low-cost indicator with high sensitivity and specificity for predicting IR in MetS patients.
Similar content being viewed by others
Abbreviations
- MetS:
-
Metabolic Syndrome
- SPISE:
-
Single Point Insulin Sensitivity Estimator
- IR:
-
Insulin Resistance
- HOMA-IR:
-
Homeostasis Model Assessment for Insulin resistance
- IRI:
-
Insulin Resistance Index
References
Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.
Morales VE. Syndrome X vs metabolic syndrome. Arch Cardiol Mex. 2006;76(Suppl 4):S173–88.
Mohan V. ICMR-India Diabetes [INDIAB] Study, Phase I Final Report (2008–2011). 2016;40
Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, et al. Metabolic syndrome and associated diseases: from the bench to the clinic. Toxicol Sci. 2018;162(1):36–42.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–23.
Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.
Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen HA, Van Haeften T, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes care. 2000;23(3):295–301.
Pacini G, Tonolo G, Sambataro M, Maioli M, Ciccarese M, Brocco E, et al. Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. Am J Physiol. 1998;274(4):E592–9.
Tura A, Sbrignadello S, Succurro E, Groop L, Sesti G, Pacini G. An empirical index of insulin sensitivity from short IVGTT:validation against the minimal model and glucose clamp indices in patients with different clinical characteristics. Diabetologia. 2010;53:144–52.
Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes. 2010;1(2):36–47.
Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Crit Rev Clin Lab Sci. 2015;52(4):180–90.
Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al. Metabolic syndrome. In: Lam DW, Le Roith D, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000–2019.
McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802–9.
Paulmichl K, Hatunic M, Hojlund K, Jotic A, Krebs M, Mitrakou A, et al. Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes mellitus: The single point insulin sensitivity estimator (SPISE). Clin Chem. 2016;62:1211–9.
Dudi P, Goyal B, Saxena V, Rabari K, Mirza AA, Naithani M, et al. Single point insulin sensitivity estimator as an index for insulin sensitivity for metabolic syndrome: A study in North Indian population. J Lab Physicians. 2019;11:244–815.
Funding
No Funding required.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rabari, K., Naithani, M., Patra, P. et al. Single-Point Insulin Sensitivity Estimator (SPISE) as a Feasible Marker of Insulin Resistance in Adult Metabolic Syndrome: Evaluated in a Hospital Based Cross-Sectional Pilot Study at Tertiary Care Centre of Uttarakhand. Ind J Clin Biochem 37, 356–360 (2022). https://doi.org/10.1007/s12291-021-00992-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-021-00992-z